Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-098-9 | CAS number: 3734-67-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Data is from NTRL report
Data source
Reference
- Reference Type:
- publication
- Title:
- Three Animal Safety Studies on Acid Red 1 (Red 2G)
- Author:
- Unilever Research U. S., IncUnilever Research U. S., Inc
- Year:
- 1 989
- Bibliographic source:
- Unilever Research U. S., Inc, 45 River Road, Edgewater. New Jersey 07020 OTS0516606-2, 1989
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: as below
- Principles of method if other than guideline:
- Red 2G was fed to C57Bl mice to evaluate the toxic nature of the test compound in a sub-acute study conducted.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Disodium 5-acetylamino-4-hydroxy-3-(phenylazo)naphthalene-2,7-disulphonate
- EC Number:
- 223-098-9
- EC Name:
- Disodium 5-acetylamino-4-hydroxy-3-(phenylazo)naphthalene-2,7-disulphonate
- Cas Number:
- 3734-67-6
- Molecular formula:
- C18H15N3O8S2.2Na
- IUPAC Name:
- disodium 5-acetamido-4-hydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonate
- Reference substance name:
- C.I. Acid Red 1
- IUPAC Name:
- C.I. Acid Red 1
- Details on test material:
- - Name of test material (as cited in study report): Red 2G- Molecular formula (if other than submission substance): C18H15N3O8S2.2Na- Molecular weight (if other than submission substance): 509.426 g/mol- Substance type: Organic- Physical state: No data available- Impurities (identity and concentrations): No data available
Constituent 1
Constituent 2
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: No data available- Age at study initiation: No data available- Weight at study initiation: 16 to 23 g- Fasting period before study: No data available- Housing: No data available- Diet (e.g. ad libitum): No data available- Water (e.g. ad libitum): No data available- Acclimation period: No data availableENVIRONMENTAL CONDITIONS- Temperature (°C): No data available- Humidity (%):No data available- Air changes (per hr): No data available- Photoperiod (hrs dark / hrs light): No data availableIN-LIFE DATES: From: To: No data available
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Red 2G, dissolved in water at appropriate concentrationsDIET PREPARATION- Rate of preparation of diet (frequency): No data available- Mixing appropriate amounts with (Type of food): No data available- Storage temperature of food: No data availableVEHICLE- Justification for use and choice of vehicle (if other than water): No data available- Concentration in vehicle: 0, 0.02%, 0.1%, 0.5% or 1.0%- Amount of vehicle (if gavage): No data available- Lot/batch no. (if required): No data available- Purity: No data available
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data available
- Duration of treatment / exposure:
- 6 weeks
- Frequency of treatment:
- Daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:0, 0.02%, 0.1%, 0.5% or 1.0% (0, 20, 100, 500 or 1000 mg/Kg bw)Basis:
- No. of animals per sex per dose:
- Total: 50- 25 bucks and 25 does
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data available
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data- Time schedule: No data- Cage side observations checked in table [No.?] were included. No dataDETAILED CLINICAL OBSERVATIONS: No data- Time schedule: No dataBODY WEIGHT: Yes- Time schedule for examinations: No dataFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: YesFOOD EFFICIENCY:- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No dataWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data- Time schedule for examinations: No dataOPHTHALMOSCOPIC EXAMINATION: No data - Time schedule for examinations:- Dose groups that were examined: No dataHAEMATOLOGY: Yes - Time schedule for collection of blood: On days 5, 8, 11, 17, 42 and 44- Anaesthetic used for blood collection: No data - Animals fasted: No data - How many animals: No data- Parameters checked in table [No.?] were examined. No dataCLINICAL CHEMISTRY: No data - Time schedule for collection of blood: No data- Animals fasted: No data - How many animals: No data- Parameters checked in table [No.?] were examined. No dataURINALYSIS: No data- Time schedule for collection of urine: No data- Metabolism cages used for collection of urine: No data - Animals fasted: No data- Parameters checked in table [No.?] were examined. No dataNEUROBEHAVIOURAL EXAMINATION: No data- Time schedule for examinations: No data- Dose groups that were examined: No data- Battery of functions tested: No data sensory activity / grip strength / motor activity / other: No dataOTHER: No data
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, All animals were subjected to full post-mortem examination immediately after death; during necropsy, liver spleen and kidneys were removed and weighed.HISTOPATHOLOGY: Yes, portions of spleen, liver, kidneys, heart, adrenals, stomach, small intestine, large intestine, bladder, lung, thymus, brain, femur, skeletal muscle and testes or uterus and ovaries were fixed in 10% formol saline. Paraffin –sections of liver, spleen and kidneys from all 50 mice were prepared by conventional methods and stained with Haematoxylin and Eosin; duplicate sections of liver, spleen and kidneys were treated by Perl's Prussian Blue Reaction (P.B.R.) to demonstrate haemosiderin. Paraffin sections of all other organs listed above were prepared from only 2 males and 2 females of each treatmont group, since experience with rats fed Red 2G suggested that no significant lesions would be detected in these organs. All organs which were not processed at this stage were retained in formol saline until histological studies had been completed and had confirmed the absence of significant lesions in organs other than spleen, liver and kidneys.During histological examination, sections of spleen, liver and kidneys were examined and scored using the “blind screening technique", whereby sections were examined at random, without reference to their group source until examination of all sections was completed. This technique was repeated three times on each section and the score finally given to each section was the average of the three recorded scores.
- Other examinations:
- No data available
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Details on results:
- Clinical signs and mortality:Mortality: No death was recorded during the studyClinical signs: No data available Body weight and weight gain: No appreciable effect on body weight gain was notedFood consumption and compound intake: No appreciable effect on food intake was notedFood efficiency: No data available Water consumption and compound intake: No data available Opthalmoscopic examination: No data available Haematology: Haematological studies revealed Heinz bodies in all blood samples taken on days 5, 8, 11, 17 and 42 or 44, from mice fed 0.5 or 1.0% Red 2G. No Heinz bodies were seen at any time in blood from mice fed 0, 0.02 or 0.1% Red 2G. No significant fall in packed cell volumes was noted in male mice fed Red 2G but in females, a trend towards lower levels was recorded in animals fed dietary levels of 0.1- 1.0% After feeding the diets for six weeks, blood samples obtained from mice fed 0.5 and 1.0% Red 2G contained appreciable levels of methaemoglobin.Clinical chemistry: No data availableUrinanalysis: No data available Neurobehaviour: No data available Organ weights: An increase in splenic size in animals fed 0.5 or 1.0% Red 2G, this observation being confirmed by subsequent comparison of relative splenic weights. In these two groups, the spleens of male animals were on average, 1.5 and 2.1 times the weight of the spleens of male mice in the control group, and those of female animals 1.4 and 1.8 times the weight of the spleens of the female mice in the control group. Histological examination of the spleen was designed to determine the factor/factors associated with its increased size and weight in animals fed 0.5 or 1.0 % Red 2G.Kidney weights of mice fed Red 2G were slightly less than those of the controls.Gross pathology: All animals were in good bodily condition and no evidence of jaundice, tissue pallor or discoloration of the kidneys was observed. The most striking differences among the treatment groups were the pink of purple discoloration of the contents of the stomach, lower small intestine and urine and enlargement of the spleen. One female rat fed a diet containing 0.5% Red 2G showed a 5mm cyst, containing clear fluid, in the hilar region of the spleen.Histopathology: Spleen: Splenic enlargement and increased spleen weight was noted which was associated with increased haemosiderin deposition, increased erythropoiesis and associated sinusoidal engorgement.Well defined sex differences were observed in the levels of splenic haemosiderin, higher levels of haemosiderin being detected in female animals fed Purified Diet or Purified Diet plus Red 2G. Due to these higher background levels of haemosiderin in female mice, the detection of small additions of haemosiderin to this background pool has proved difficult, and it must be concluded that, female mice, in this trial, were a less sensitive indicator of splenic haemosiderin levels than males. This was particularly so in the case of red pulp reticular impregnation in which no significant difference was observed among the females of any treatment group.Histological examination of the splenic cyst observed in the hilar region of a female mouse, fed a diet containing 0.5% Red 2G, revealed this thin walled cyst to be lined by cuboidal/Columnar epithelium and was closely associated with a fragment of pancreas. From the location of this cyst, it seemed probable that it had originated from an occluded pancreatic duct.Liver:No evidence of toxic degenerative change or an increase in the haemosiderin content of this organ was appreciated, even in animals fed 1.0% Red 2G. No haemosiderin was observed in the cytoplasm of Kupffer or parenchymal cells of any animal in this trial while the levels of haemosiderin impregnation of sinusoidal endothelium were extremely low in all control and treatment groups. Against this very low background level of haemosiderin in control animals, any significant increase in hepatic haemosiderin could have been readily detectable and it is therefore considered that the feeding of up to 1.0% Red 2G has failed to increase the amount of this iron containing pigment in the livers of mice.Occasional tiny foci of hepatic necrosis were observed in a few mice in almost all the control and treatment groups. The incicidence and the severity of these foci were not influenced by the feeding of Red 2G.Kidneys: Cortical tubular hyaline casts, in small numbers, were noted in the majority of male mice but the number and size of these casts was not influenced by the feeding of Red 2G. In contrast, only an occasional cast was observed in female mice and these were distributed in random manner throughout the control and treatment groups.Careful scrutiny of the epithelium of the proximal convoluted tubules of the control animals revealed only small quantities of haemosiderin, this being present in finely granular form. Against this low level background, any increase in haemosiderin in this site was readily detectable.Bone Marrow:Erythroid hyperplasia of bone marrow was well defined in all mice fed 0.5 - 1.0% Red 2G but no significant lesions were observed in animals fed dietary levels of 0.02 – 0.1%.Lungs: Lymphoreticular hyperplasia, of mild to moderate severity was identified in the majority of animals and was dose independent.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 20 mg/kg bw (total dose)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects noted at the mentioned dose level
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table: Average Body weight gain
Treatment group | Average body weight (g) |
0.02% | 22.3 |
0.1% | 24.8 |
0.5% | 20.3 |
1.0% | 22.5 |
Table: Food consumption and compound intake
Treatment group | Average food intake in 42 days (g) | Average daily food intake (g) | Average daily Red 2G intake (mg) | Average daily Red2G intake mg/Kg bw |
0.02% | 592 | 1.41 | 0.28 | 12.5 |
0.1% | 651 | 1.55 | 1.5 | 60.5 |
0.5% | 620 | 1.48 | 1.7 | 354.7 |
1.0% | 574 | 1.37 | 13.7 | 608.9 |
Table: Gross pathology
Treatment group | Stomach | Lower small intestine | Urine | Spleen |
0.0% | NL | NL | NAD | NL |
0.02% | Pink | Pale Pink | NAD | NL |
0.1% | Bright Pink | Pink | NAD | NL |
0.5% | Bright Pink | Pink | NAD | Enlarged, Dark |
1.0% | Bright Pink | Purple | Pink | Enlarged, Dark |
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) for the test compound Red 2G is found to be 0.02% (20 mg/Kg bw).
- Executive summary:
Red 2G was fed to C57Bl mice to evaluate the toxic nature of the test compound in a sub-acute study conducted.
Red 2G was fed to C57Bl. mice at dietary levels of 0, 0.02. 0.1. 0.5 and 1.0%(0, 20, 100, 500 or 1000 mg/Kg bw). The toxic effects included the development of Heinz bodies in red blood cells, methaemoglobinemia,. splenic enlargement, accelerated splenic erythropolesis and increased levels of haemosiderin in splenic macrophages. These findings indicated that Red 2G was capable of producing haemolysis of red blood cells in mice.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.